Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Quince Therapeutics Logo
Quince Therapeutics Growth Score
87
CB Rank
10521
Heat Score
77
Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States11-50 quincetx.com/
Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics
Overview

Quince Therapeutics
Total Funding
obfuscation
Growth Score
87
Heat Score
77

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score87
5 pts
in past quarter
Heat Score 77
16 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Quince Therapeutics

CB Rank
10521
Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States11-50 quincetx.com/
Biotechnology
Health Care
Medical
Pharmaceutical
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Cortexyme, Inc.
Also Known As Cortexyme
Operating Status Active
Stock Symbol  NASDAQ:QNCX
Company Type For Profit
Founders  Brendan Hannah, Casey Lynch, Kristen Gafric, Stephen Dominy
About the Company

Quince Therapeutics is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Quince Therapeutics is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and

Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Phone Number +1 415 910 5717
Diversity Spotlight 
Women Founded
Women Led
Predictions & Insights

Growth Insight

See this Growth Insight
Quince Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

eDSP
A drug/device combination that encapsulates dexamethasone sodium phosphate into a patient’s own red blood cells for treating Ataxia-Telangiectasia.
AIDE Technology Platform
An automated drug/device platform that encapsulates drugs into a patient’s own red blood cells for therapeutic delivery.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 8
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity
obfuscation
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
13
obfuscation
Balyasny Asset ManagementPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
SilverArc Capital Logo
SilverArc Capital
—
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
—
SilverArc Capital Logo
SilverArc Capital
—
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
—
SilverArc Capital Logo
SilverArc Capital
—
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
—
SilverArc Capital Logo
SilverArc Capital
—
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
—
SilverArc Capital Logo
SilverArc Capital
—
Post-IPO Equity - Quince Therapeutics Logo
Post-IPO Equity - Quince Therapeutics
—

Investments

Number of Acquisitions 3

Investment Breakdown

Number of Acquisitions 3
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 13 Board Members and Advisors 10 Contacts 31

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 30, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 19, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

1,416
-64.48%
 in past month

IT Spend

$2.5MThis year, Quince Therapeutics is projected to spend $2.5M on IT, according to Aberdeen.

Active Website Tech Count

29Quince Therapeutics is actively using 29 technologies for its website, according to BuiltWith. These include Apple Mobile Web Clips Icon, HSTS, and  Euro.

Total IP

9The intellectual property of Quince Therapeutics includes 8 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery. Additionally, Quince Therapeutics has 1 registered trademark in the 'Pharmaceutical, veterinary and sanitary products' class, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Quince Therapeutics's headquarters? Quince Therapeutics is located in South San Francisco, California, United States.Who invested in Quince Therapeutics? Quince Therapeutics has 30 investors including SilverArc Capital and  Eventide.When was the last funding round for Quince Therapeutics? Quince Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Quince Therapeutics's competitors? Alternatives and possible competitors to Quince Therapeutics may include Retro Biosciences, LEXEO Therapeutics, and  Dyne Therapeutics.How much funding has Quince Therapeutics raised to date? Quince Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(790e229 1)
|